Clinical Trial Detail

NCT ID NCT03044730
Title Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Northwestern University

breast cancer

Her2-receptor negative breast cancer

triple-receptor negative breast cancer


Capecitabine + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST